In a small‐sample study involving 36 individuals with NSCLC and EGFR mutation who received gefitinib or erlotinib therapy, a marked dissimilarity was observed in the mOS of individuals with 19‐Del and those with 21‐L858R (38 vs. 17 months; p = 0.04).24 Here, EGFR is linked to non-small cell lung carcinoma.